drugset
drugset / Trial / NCT04143789

Evaluation of AP-002 in Patients With Solid Tumors

NCT04143789 ↗

Phase 1/2 Unknown 61 enrolled Altum Pharmaceuticals INC
SequentialOpen-labelTreatment

Summary

The purpose of this trial is to define an effective and safe dose of AP-002 in advanced or recurrent solid tumors for which there are no standard therapies to use in subsequent studies in advanced or recurrent breast, non-small cell lung cancer (NSCLC) or prostate cancers.

Timeline

Start
2019-09-27
Primary completion
2021-03
Completion
2021-04

Drugs

EvaluationDrugModalityDoseRoute
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 8 mg Oral
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 16 mg Oral
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 32 mg Oral
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 64 mg Oral
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 84 mg Oral
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 108 mg Oral
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 140 mg Oral
Subject TRIS(8-HYDROXYQUINOLINATO)GALLIUM Unknown 180 mg Oral

Indications

cancer